Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Biosimilar Fda'

Biosimilar Fda published presentations and documents on DocSlides.

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
MODULE 8. Follow-on drugs: generic, biosimilar
MODULE 8. Follow-on drugs: generic, biosimilar
by alida-meadow
& non-biological similar medicinal products ....
PhAMA Position on Biosimilar Medicines
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
U.S. Biosimilars: An Introduction
U.S. Biosimilars: An Introduction
by calandra-battersby
Disclaimers. :. By 2016, 7 of the top 10 pharmace...
Biosimilar Biological Products
Biosimilar Biological Products
by luanne-stotts
2016 . Clinical Investigator . Training Course. S...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
The generic and biosimilar
The generic and biosimilar
by alida-meadow
perspective. Warwick Smith. Director General BGMA...
What You Need to Know About
What You Need to Know About
by marina-yarberry
Biosimilars. : Products, Recent Deals, IP Issues ...
Is Australia ready for
Is Australia ready for
by liane-varnes
biosimilar. . ?. David Lim, Julie Hepworth, Lis...
Acceptable changes in quality attributes of glycosylated bi
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Biosimilars
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
Biosimilars in RA: A Blessing or a Curse?
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Concurrent Session 1B
Concurrent Session 1B
by yoshiko-marsland
View . from the Life Sciences . Industry. Moderat...
Biosimilars in the Real World
Biosimilars in the Real World
by liane-varnes
Introduction/Overview . PLANETRA Extension Study:...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
by alida-meadow
Richard Montes, Ph.D.. Hospira. , a Pfizer compan...
Understanding Biologics Biologics and Biosimilars
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Biological Products: concepts, naming,
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Applying Biosimilars in Hematologic Cancers
Applying Biosimilars in Hematologic Cancers
by conchita-marotz
This program will include a discussion of off-lab...
Application of Biosimilars in RA IN Clinical Practice:
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges.  . Introduction. Diff...
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
by carla
Adoption by CHMP for release for consultation24 Ma...
INSIGHTS INTO THE MARKET
INSIGHTS INTO THE MARKET
by summer
FOR INFLIXIMABTable of ContentsThe Evolving Landsc...
Budget impact and cost-effectiveness of oncology
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
  What is the value of Real-World Evidence for Biosimilars?
  What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
A QUM partnership approach to regulating
A QUM partnership approach to regulating
by liane-varnes
biosimilars. in Australia. David Lim, Evan Siege...
Conference Series LLC
Conference Series LLC
by alida-meadow
Conferences. Conference Series LLC . is a pioneer...
Biosimilars 2012 AIPLA Webinar
Biosimilars 2012 AIPLA Webinar
by stefany-barnette
September 25, 2012. 1. Denise. Kettelberger, PhD...
High-resolution SPR surrogate potency assay to facilitate comparability and biosimilar studies
High-resolution SPR surrogate potency assay to facilitate comparability and biosimilar studies
by test
Veronica Fridh, GE Healthcare, Uppsala, Sweden No...
Biosimilars & EU regulation
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
About OMICS Group OMICS Group International is an amalgamation of 
About OMICS Group OMICS Group International is an amalgamation of 
by sherrill-nordquist
Open Access publications.  and worldwide interna...
ASBM Biosimilars US Prescribers and Biosimilars Naming
ASBM Biosimilars US Prescribers and Biosimilars Naming
by min-jolicoeur
Kevin Olson, CEO. Industry Standard Research. Kev...
National Pharmacy Practice
National Pharmacy Practice
by debby-jeon
Gene Dorr . Area Vice President, PBM Consulting. ...
Latin American Physician Perspectives on Biosimilars
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
Biosimilars in emerging markets- regulatory and Commercial considerations
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Improving Your Formulary and Denials Management
Improving Your Formulary and Denials Management
by trinity
Zinkeng Asonganyi, PharmD. Director of Pharmacy Se...
Medicare Part B Step Therapy Programs
Medicare Part B Step Therapy Programs
by elina
Page 1 of 10 UnitedHealthcare Medicare Advantag...
1 Immunogenicity The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Challenges in Assessing Therapeutic Equivalence of
Challenges in Assessing Therapeutic Equivalence of
by thomas
Nanosimilars. Beat . Flühmann. Global Lead NBCD ....
Regulatory aspects and review
Regulatory aspects and review
by mary
of EMA authorized . biosimilars. Session “Biosim...